Santen Pharmaceutical Co., Ltd.

Shinji Takaoka

Kenji Kawashima

Tomoko Oda

Yusuke Yamazaki

Daisuke Shii

Takahiro Matsuyama

Takahiro Honda

Mamoru Matsuda

Hiroshi Enomoto

Shin-ichiro Hirai

Yasutaka Fujioka

Koji Ohashi

Yukie Fujita

Hiroaki Kurashima

The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.

[4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof

The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.

[4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof

A compound represented by the following general formula (1) or a salt thereof. Rrepresents a halogen atom and so on; Rand Reach represent a hydrogen atom and so on; Rand Reach represent a hydrogen atom and so on, or Rand Rmay form an oxo group; Rand Reach represent a lower alkyl group optionally having a substituent and so on, or they may bind to each other to form a nitrogen-containing heterocyclic ring which may be substituted by one or plural R; Rrepresents an aryl group optionally having a substituent and so on; ring A represents a benzene ring and so on; and m represents 0, 1 or 2. 

Compound having PARP inhibitory activity

Growing community of inventors

Ikoma, Japan

Shinji Takaoka